一项新的研究显示,与早期药物治疗相比,等待治疗预产期婴儿的专利结构动脉会改善存活率并减少并发症。 A new study shows waiting to treat patent ductus arteriosus in preterm infants improves survival and reduces complications compared to early drug therapy.

美国医学协会期刊《2025年12月9日美国医学协会杂志》刊登了一个新的临床试验,发现对极早期婴儿的专利结构动脉学(PDA)采取“观望”办法,比早期药物治疗更能存活。 A new clinical trial published December 9, 2025, in the Journal of the American Medical Association found that a "wait and see" approach to patent ductus arteriosus (PDA) in extremely preterm infants leads to better survival rates than early drug treatment. 在22至28周之间出生的482名婴儿中,在预产期管理组中,只有4%的婴儿在36周的月经后年龄前死亡,而在接受不代梅西辛、伊布普罗芬或乙胺芬治疗的婴儿中,这一比例接近10%。 Among 482 infants born between 22 and 28 weeks, only 4% in the expectant management group died by 36 weeks postmenstrual age, compared to nearly 10% in those treated with indomethacin, ibuprofen, or acetaminophen. 研究发现早期药物治疗没有给生存带来任何好处,并查明严重并发症,包括败血症和肠道组织死亡的风险增加,这很可能是药物副作用所致。 The study found no survival benefit from early medication and identified increased risks of serious complications, including sepsis and intestinal tissue death, likely due to drug side effects. 这些调查结果表明,避免早期干预可能比较安全,促使专家建议重新考虑目前的治疗做法,并与医生讨论基于观察的战略。 These findings suggest that avoiding early intervention may be safer, prompting experts to recommend reconsidering current treatment practices and discussing observation-based strategies with doctors.